"Hemorrhage" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bleeding or escape of blood from a vessel.
| Descriptor ID |
D006470
|
| MeSH Number(s) |
C23.550.414
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hemorrhage".
Below are MeSH descriptors whose meaning is more specific than "Hemorrhage".
This graph shows the total number of publications written about "Hemorrhage" by people in this website by year, and whether "Hemorrhage" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 1 | 2 |
| 1998 | 4 | 0 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2003 | 0 | 4 | 4 |
| 2004 | 3 | 4 | 7 |
| 2005 | 1 | 5 | 6 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 6 | 6 |
| 2008 | 3 | 1 | 4 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 7 | 9 |
| 2011 | 3 | 4 | 7 |
| 2012 | 4 | 7 | 11 |
| 2013 | 5 | 7 | 12 |
| 2014 | 4 | 5 | 9 |
| 2015 | 5 | 5 | 10 |
| 2016 | 15 | 7 | 22 |
| 2017 | 7 | 7 | 14 |
| 2018 | 6 | 6 | 12 |
| 2019 | 7 | 8 | 15 |
| 2020 | 8 | 6 | 14 |
| 2021 | 6 | 7 | 13 |
| 2022 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemorrhage" by people in Profiles.
-
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
-
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
-
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022 08 11; 8(5):492-502.
-
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556.
-
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
-
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circ Cardiovasc Interv. 2022 04; 15(4):e009495.
-
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 12 01; 42(45):4624-4634.
-
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
-
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
-
Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. Circ Cardiovasc Interv. 2021 09; 14(9):e010392.